Literature DB >> 27646423

Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Stable Angina in Advanced CKD: A Decision Analysis.

Aisha Khattak1, Ernest I Mandel2, Matthew R Reynolds3, David M Charytan4.   

Abstract

BACKGROUND: Percutaneous coronary intervention (PCI) use is low in the setting of stable symptomatic angina in individuals with advanced chronic kidney disease (CKD) despite high cardiovascular risk in this population, and PCI is frequently deferred out of concern for precipitating dialysis therapy. Whether this is appropriate is uncertain, and patient-centered data comparing the relative risks and benefits of continued medical therapy versus PCI in patients with advanced CKD and stable angina are scarce. STUDY
DESIGN: Decision analysis. SETTING & POPULATION: Hypothetical cohort of individuals with advanced CKD (stages 4-5 with estimated glomerular filtration rates ≤ 20mL/min/1.73m2) and stable angina. MODEL, PERSPECTIVE, & TIMELINE: A Markov model with a Monte Carlo simulation through 12 cycles, that is, 3 years of 3-month intervals, with 10,000 microsimulations predicted mean quality-adjusted life-years. INTERVENTION: PCI first, medical management, or dialysis (hemodialysis [HD]) followed by PCI. OUTCOMES: Outcomes modeled were progression to HD therapy (for those not assigned to the preemptive HD strategy), catheter infection, and death.
RESULTS: Our analysis showed mean quality-adjusted life-years of 1.103 ± 0.69 for PCI first, 1.088±0.70 for medical management, and 0.670±0.58 for HD followed by PCI. Probabilistic sensitivity analysis found PCI as the preferred strategy > 60% of the time. LIMITATIONS: Values for probabilities and utilities were estimated and/or derived from multiple sources that were not uniform in their populations in terms of age, comorbid condition burden, and degree of kidney failure, and several simplifying assumptions were made.
CONCLUSIONS: Our analysis demonstrates that quality-adjusted life expectancy is similar for the PCI first and medical management strategies in patients with advanced CKD with stable angina and that the decision depends on patient preferences other than those incorporated in our model. Both strategies are superior to preemptive dialysis.
Copyright © 2016 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Percutaneous coronary intervention (PCI); advanced renal failure; cardiovascular intervention; catheter infection; chronic kidney disease (CKD); contrast nephropathy; contrast-induced nephropathy (CIN); death; decision model; hemodialysis; medical management; mortality; quality of life; quality-adjusted life-year (QALY); stable angina; therapeutic nihilism

Mesh:

Year:  2016        PMID: 27646423      PMCID: PMC5329119          DOI: 10.1053/j.ajkd.2016.07.024

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  35 in total

1.  Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra.

Authors:  Karl Claxton; Mark Sculpher; Chris McCabe; Andrew Briggs; Ron Akehurst; Martin Buxton; John Brazier; Tony O'Hagan
Journal:  Health Econ       Date:  2005-04       Impact factor: 3.046

2.  Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables.

Authors:  George Dangas; Ioannis Iakovou; Eugenia Nikolsky; Eve D Aymong; Gary S Mintz; Nicholas N Kipshidze; Alexandra J Lansky; Issam Moussa; Gregg W Stone; Jeffrey W Moses; Martin B Leon; Roxana Mehran
Journal:  Am J Cardiol       Date:  2005-01-01       Impact factor: 2.778

Review 3.  Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials.

Authors:  Seema Pursnani; Frederick Korley; Ravindra Gopaul; Pushkar Kanade; Newry Chandra; Richard E Shaw; Sripal Bangalore
Journal:  Circ Cardiovasc Interv       Date:  2012-08-07       Impact factor: 6.546

4.  Health status and quality of life in patients with stable coronary artery disease and chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post hoc findings from the COURAGE trial).

Authors:  Steven P Sedlis; Claudine T Jurkovitz; Pamela M Hartigan; Paul Kolm; David S Goldfarb; Jeffrey D Lorin; Marcin Dada; David J Maron; John A Spertus; G B John Mancini; Koon K Teo; William E Boden; William S Weintraub
Journal:  Am J Cardiol       Date:  2013-09-03       Impact factor: 2.778

5.  Comparing the psychometric properties of preference-based and nonpreference-based health-related quality of life in coronary heart disease. Canadian Collaborative Cardiac Assessment Group.

Authors:  L Lalonde; A E Clarke; L Joseph; T Mackenzie; S A Grover
Journal:  Qual Life Res       Date:  1999-08       Impact factor: 4.147

6.  Preventing radiocontrast-induced nephropathy in chronic kidney disease patients undergoing coronary angiography.

Authors:  Yao-Min Hung; Shoa-Lin Lin; Shih-Yuan Hung; Wei-Chun Huang; Paul Yung-Pou Wang
Journal:  World J Cardiol       Date:  2012-05-26

Review 7.  Contrast-induced nephropathy: what are the true clinical consequences?

Authors:  Michael Rudnick; Harold Feldman
Journal:  Clin J Am Soc Nephrol       Date:  2008-01       Impact factor: 8.237

Review 8.  Contrast-induced nephropathy.

Authors:  Tereza Pucelikova; George Dangas; Roxana Mehran
Journal:  Catheter Cardiovasc Interv       Date:  2008-01-01       Impact factor: 2.692

9.  Should the arteriovenous fistula be created before starting dialysis?: a decision analytic approach.

Authors:  Swapnil Hiremath; Greg Knoll; Milton C Weinstein
Journal:  PLoS One       Date:  2011-12-07       Impact factor: 3.240

10.  Age and association of kidney measures with mortality and end-stage renal disease.

Authors:  Stein I Hallan; Kunihiro Matsushita; Yingying Sang; Bakhtawar K Mahmoodi; Corri Black; Areef Ishani; Nanne Kleefstra; David Naimark; Paul Roderick; Marcello Tonelli; Jack F M Wetzels; Brad C Astor; Ron T Gansevoort; Adeera Levin; Chi-Pang Wen; Josef Coresh
Journal:  JAMA       Date:  2012-12-12       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.